424 related articles for article (PubMed ID: 18998037)
1. Epigenome: a new target in cancer therapy.
Giacinti L; Vici P; Lopez M
Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic information and estrogen receptor alpha expression in breast cancer.
Giacinti L; Claudio PP; Lopez M; Giordano A
Oncologist; 2006 Jan; 11(1):1-8. PubMed ID: 16401708
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
4. [Epigenome and cancer: new possibilities of cancer prevention and therapy?].
Paluszczak J; Baer-Dubowska W
Postepy Biochem; 2005; 51(3):244-50. PubMed ID: 16381168
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic alterations and cancer: new targets for therapy.
Allen A
IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
De la Cruz-Hernández E; Perez-Plasencia C; Pérez-Cardenas E; Gonzalez-Fierro A; Trejo-Becerril C; Chávez-Blanco A; Taja-Chayeb L; Vidal S; Gutiérrez O; Dominguez GI; Trujillo JE; Duenas-González A
Oncol Rep; 2011 Feb; 25(2):399-407. PubMed ID: 21152880
[TBL] [Abstract][Full Text] [Related]
8. DNA demethylating agents and epigenetic therapy of cancer.
Mani S; Herceg Z
Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics and cancer treatment.
Kristensen LS; Nielsen HM; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy.
Grønbaek K; Treppendahl M; Asmar F; Guldberg P
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):389-96. PubMed ID: 18947362
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
Vaissière T; Sawan C; Herceg Z
Mutat Res; 2008; 659(1-2):40-8. PubMed ID: 18407786
[TBL] [Abstract][Full Text] [Related]
14. Unraveling the epigenetic code of cancer for therapy.
Smith LT; Otterson GA; Plass C
Trends Genet; 2007 Sep; 23(9):449-56. PubMed ID: 17681396
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation and cancer.
Das PM; Singal R
J Clin Oncol; 2004 Nov; 22(22):4632-42. PubMed ID: 15542813
[TBL] [Abstract][Full Text] [Related]
16. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
Murgo AJ
Semin Oncol; 2005 Oct; 32(5):458-64. PubMed ID: 16210086
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic biomarkers for human cancer: the time is now.
Mulero-Navarro S; Esteller M
Crit Rev Oncol Hematol; 2008 Oct; 68(1):1-11. PubMed ID: 18430583
[TBL] [Abstract][Full Text] [Related]
18. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
19. The clinical application of targeting cancer through histone acetylation and hypomethylation.
Gilbert J; Gore SD; Herman JG; Carducci MA
Clin Cancer Res; 2004 Jul; 10(14):4589-96. PubMed ID: 15269129
[TBL] [Abstract][Full Text] [Related]
20. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Conley BA; Wright JJ; Kummar S
Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
